Biotech Values

[DewDiligence]

>ZGEN – Yes its early, but 300 vials for Feb is a bit disappointing.<

It is more than just a little bit disappointing—it’s awful.

I went through this kind of thing with Tyzeka, where the initial numbers were bad and they never improved to the degree I had expected.

If the crappy Recothrom numbers persist, you’ll see a lot of excuses on the message boards because it’s hard for investors to admit that a company’s first drug may be a commercial flop.